Video

Details of Pfizer’s Investigation Into an Omicron-Specific Vaccine for Adults Aged 18 to 55

Sachin Nagrani, MD, the medical director of Heal, discusses Pfizer’s research assessing an Omicron-specific vaccine for adults aged 18 to 55 years.

Pharmacy Times interviewed Sachin Nagrani, MD, the medical director of Heal, on Pfizer’s research assessing an Omicron-specific vaccine for adults aged 18 to 55 years.

During the interview, Nagrani provided details regarding the Pfizer Omicron-specific vaccine under investigation, when the vaccine may become available to be sent to pharmacies for administration to patients, whether Pfizer is the only company looking to develop a specific variant-targeted vaccine, and whether booster shots that are not variant-specific are still beneficial for patients to pursue.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Austin Texas | Image credit: Kevin Ruck - stock.adobe.com
Pharmacy Times OPC